https://www.businesswire.com/news/home/20180831005055/en/

PETACH TIKVA, Israel--(BUSINESS WIRE)--Aug 31, 2018--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today reported financial results for the three months ended June 30, 2018 and provided clinical and corporate updates.

Clinical Development Program and Corporate Highlights of the Second Quarter 2018 and Recent Weeks Include: